No profile photo available

Joshua A. Jacobs, PhD, PharmD

Academic Information

Departments Primary - Internal Medicine , Adjunct - Pharmacotherapy

Divisions: Cardiovascular Medicine

Board Certification

  • Board of Pharmacy Specialties (Sub: Cardiology Pharmacy)

Education History

Undergraduate University of Toledo College of Pharmacy and Pharmaceutical Sciences
 BPharm
Professional Medical University of Toledo College of Pharmacy and Pharmaceutical Sciences
 PharmD
Residency Intermountain Medical Center
 Resident
Residency Ohio State University Wexner Medical Center
 Resident
Doctoral Training University of Utah Spencer Fox Eccles School of Medicine
 PhD

Selected Publications

Journal Article

  1. Zheutlin AR, Jacobs JA, Bress AP (2025). High-Density Lipoprotein Cholesterol and Statin Use Among U.S. Adults With Intermediate 10-Year Predicted ASCVD Risk. JACC Adv, 4(6 Pt 2), 101725. (Read full article)
  2. Cintron MA, Baumer Y, Pang APS, Aquino Peterson EM, Ortiz-Whittingham LR, Jacobs JA, Sharda S, Potharaju KA, Baez AS, Gutierrez-Huerta CA, Ortiz-Chaparro EN, Collins BS, Mitchell VM, Saurabh A, Mendelsohn LG, Redekar NR, Paul S, Corley MJ, Powell-Wiley T (2025). Associations between the neural-hematopoietic-inflammatory axis and DNA methylation of stress-related genes in human leukocytes: Data from the Washington, D.C. cardiovascular health and needs assessment. Brain, behavior, & immunity - health, 45, 100976. (Read full article)
  3. Zheutlin AR, Jacobs JA, Niforatos JD, Chaitoff (2025). Prevalence of prescription medication use that can exacerbate heart failure among US adults with heart failure. Pharmacotherapy, 45(3), 155-160. (Read full article)
  4. Bullock G, Jacobs JA, Carey JR, Pan IZ, Kinsey MS, Sideris K, Kapelios CJ, Stehlik J, Fang JC, Das S, Carter S (2025). Patterns of diuretic titration during inpatient management of acute decompensated heart failure. American heart journal, 282, 30-39. (Read full article)
  5. Jacobs JA, Ayodele I, Bress AP, Sterling MR, Pandey A, Derington CG, Zheutlin AR, Shah KS, Greene SJ, Alhanti B, Blanco R, Fonarow G (2025). Social Determinants of Health and Disparities in Guideline-Directed Medical Therapy Optimization for Heart Failure. Circulation. Heart failure, 18(1), e012357. (Read full article)
  6. Xu Y, Derington CG, Addo DK, He T, Jacobs JA, Mohanty AF, An J, Cushman WC, Ho PM, Bellows BK, Cohen JB, Bress A (2024). Trends in Initial Antihypertensive Medication Prescribing Among >2.8¿Million Veterans Newly Diagnosed With Hypertension, 2000 to 2019. Journal of the American Heart Association, 13(20), e036557. (Read full article)
  7. Zheutlin AR, Jacobs JA, Stamm B, Royan (2024). Lipoprotein(a) among normotensive patients and risk of incident hypertension. Journal of clinical hypertension (Greenwich, Conn.), 26(11), 1313-1317. (Read full article)
  8. Jacobs JA, Carter SJ, Bullock G, Carey JR, Pan IZ, Kinsey MS, Zheutlin AR, Kapelios CJ, Raju S, Fang JC, Shah KS, Bress A (2024). Optimal Initial Intravenous Loop Diuretic Dosing in Acute Decompensated Heart Failure. JACC. Advances, 3(10), 101250. (Read full article)
  9. Jacobs JA, Rodgers A, Bellows BK, Hernandez I, Wang N, Derington CG, King JB, Zheutlin AR, Whelton PK, Egan BM, Cushman WC, Bress A (2024). Use and Cost Patterns of Antihypertensive Medications in the United States From 1996 to 2021. Hypertension (Dallas, Tex., 81(11), 2307-2317. (Read full article)
  10. Zheutlin AR, Sharareh N, Guadamuz JS, Berchie RO, Derington CG, Jacobs JA, Mondesir FL, Alexander GC, Levitan EB, Safford M, Vos RO, Qato DM, Bress A (2024). Association Between Pharmacy Proximity With Cardiovascular Medication Use and Risk Factor Control in the United States. Journal of the American Heart Association, 13(5), e031717. (Read full article)
  11. Jacobs JA, Derington CG, Zheutlin AR, King JB, Cohen JB, Bucheit J, Kronish IM, Addo DK, Morisky DE, Greene TH, Bress A (2024). Association Between Self-Reported Medication Adherence and Therapeutic Inertia in Hypertension: A Secondary Analysis of SPRINT (Systolic Blood Pressure Intervention Trial). Journal of the American Heart Association, 13(3), e031574. (Read full article)
  12. Jacobs JA, Zheutlin AR, Derington CG, King JB, Pandey A, Bress A (2023). Glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter 2 inhibitor use among adults with diabetes mellitus by cardiovascular-kidney disease risk: National Health and Nutrition Examination Surveys, 2015-2020. American journal of preventive cardiology, 17, 100624. (Read full article)
  13. Mentias A, Keshvani N, Sumarsono A, Desai R, Khan MS, Menon V, Hsich E, Bress AP, Jacobs J, Vasan RS, Fonarow GC, Pandey (2024). Patterns, Prognostic Implications, and Rural-Urban Disparities in Optimal GDMT Following HFrEF Diagnosis Among Medicare Beneficiaries. JACC. Heart failure, 12(6), 1044-1055. (Read full article)
  14. Zheutlin AR, Addo DK, Jacobs JA, Derington CG, Herrick JS, Greene T, Stulberg EL, Berlowitz DR, Williamson JD, Pajewski NM, Supiano MA, Bress A (2023). Evidence for Age Bias Contributing to Therapeutic Inertia in Blood Pressure Management: A Secondary Analysis of SPRINT. Hypertension (Dallas, Tex., 80(7), 1484-1493. (Read full article)
  15. King JB, Berchie RO, Derington CG, Marcum ZA, Scharfstein DO, Greene TH, Herrick JS, Jacobs JA, Zheutlin AR, Bress AP, Cohen J (2023). New Users of Angiotensin II Receptor Blocker-Versus Angiotensin-Converting Enzyme Inhibitor-Based Antihypertensive Medication Regimens and Cardiovascular Disease Events: A Secondary Analysis of ACCORD-BP and SPRINT. Journal of the American Heart Association, 12(17), e030311. (Read full article)
  16. Zheutlin AR, Jacobs JA, Derington CG, Chaitoff A, Navar AM, Bress A (2023). Age-based disparities in statin use for primary prevention in US adults: National Health and Nutrition Examination Surveys 2013-2020. Journal of clinical lipidology, 17(5), 688-693. (Read full article)
  17. King JB, Derington CG, Herrick JS, Jacobs JA, Zheutlin AR, Conroy MB, Cushman WC, Bress A (2023). Single-Pill Combination Product Availability of the Antihypertensive Regimens Used for Intensive Systolic Blood Pressure Treatment in the Systolic Blood Pressure Intervention Trial. Hypertension (Dallas, Tex., 80(8), 1749-1758. (Read full article)
  18. Derington CG, Bress AP, Herrick JS, Jacobs JA, Zheutlin AR, Berchie RO, Conroy MB, Cushman WC, King J (2023). Antihypertensive Medication Regimens Used by US Adults With Hypertension and the Potential for Fixed-Dose Combination Products: The National Health and Nutrition Examination Surveys 2015 to 2020. Journal of the American Heart Association, 12(11), e028573. (Read full article)
  19. Jacobs JA, Addo DK, Zheutlin AR, Derington CG, Essien UR, Navar AM, Hernandez I, Lloyd-Jones DM, King JB, Rao S, Herrick JS, Bress AP, Pandey (2023). Prevalence of Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and 10-Year Disease Risk in the US: National Health and Nutrition Examination Surveys, 2013 to March 2020. JAMA cardiology, 8(5), 443-452. (Read full article)
  20. Clark JL, Jacobs JA, Watanabe AH, Catino AB, Dechand J (2023). Evaluation of Safety and Efficacy of Intravenous Digoxin Loading Doses Based on Ideal Body Weight. The Annals of pharmacotherapy, 57(10), 1154-1161. (Read full article)
  21. Cisowska T, Pan IZ, Biskupiak J, Shah KS, Fang JC, Jacobs J (2022). Metolazone Versus Intravenous Chlorothiazide for Decompensated Heart Failure Sequential Nephron Blockade: A Retrospective Cohort Study. Journal of cardiac failure, 28(8), 1367-1371. (Read full article)
  22. Jacobs JA, Pickworth K, Boudoulas KD, Hinkley M, McLaughlin E, Blais (2019). Outcomes for Cancer Patients with Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Cardiovascular revascularization medicine, 20(8), 711-715. (Read full article)
  23. Derington CG, Berchie RO, Greene T, Jacobs JA, Moran AE, Xu Y, Narita K, Zheutlin AR, Cohen JB, Shimbo D, Bress A (2025). Using PREVENT Equations to Compare Intensive vs Standard Systolic Blood Pressure Control for Primary Prevention in SPRINT. Journal of the American College of Cardiology, 86(17), 1437-1448. (Read full article)
  24. Derington CG, Berchie RO, Mohanty AF, Jacobs JA, Xu Y, King JB, Rethy L, Cushman WC, Zickmund SL, Ho PM, Raghavan S, Cohen JB, Bress A (2025). First-Line ß-Blocker Use for Hypertension in the Veterans Health Administration. JAMA network open, 8(8), e2529026. (Read full article)

Review

  1. Todd OM, Knight M, Jacobs JA, Derington CG, Sheppard JP, Bress A (2024). Pharmacologic Treatment of Hypertension in Older Adults. Clinics in geriatric medicine, 40(4), 629-644. (Read full article)
  2. Osei Baah F, Sharda S, Davidow K, Jackson S, Kernizan D, Jacobs JA, Baumer Y, Schultz CL, Baker-Smith CM, Powell-Wiley T (2024). Social Determinants of Health in Cardio-Oncology: Multi-Level Strategies to Overcome Disparities in Care: JACC: CardioOncology State-of-the-Art Review. JACC. CardioOncology, 6(3), 331-346. (Read full article)
  3. Jacobs JA, Jahangir E, Ryan J (2022). Differentiating pulmonary hypertension associated with protein kinase inhibitors. Pulmonary circulation, 12(2), e12075. (Read full article)
  4. Jacobs JA, Shah RU, Bress A (2022). Asymptomatic hypertension in the hospital setting: primum non nocere. Journal of human hypertension, 36(9), 781-784. (Read full article)
  5. Mayeux JD, Pan IZ, Dechand J, Jacobs JA, Jones TL, McKellar SH, Beck E, Hatton ND, Ryan J (2021). Management of Pulmonary Arterial Hypertension. Current cardiovascular risk reports, 15(1), 2. (Read full article)
  6. Pickworth KK, Blais D, Bagnola A, Barcelona R, Boyd JM, Brink H, Chilbert M, Galipeau D, Gengler B, Gerlach AT, Hayes C, Jacobs J, Kazmi H, Lavelle R, Lindsley J, Macaulay TE, Militello MA, Orzel L, Patel S, Simone P, Tasca K, Varnado S, Zoubek (2020). COVID-19 pandemic: Challenges and solutions from the cardiology pharmacist's perspective. Journal of the American College of Clinical Pharmacy, 3(6), 1138-1146. (Read full article)
  7. Pan IZ, Carey JR, Jacobs JA, Dechand J, Sessions JJ, Sorensen T, Penn BA, Mayeux JD, Hatton ND, Ryan J (2020). Transitioning Between Prostanoid Therapies in Pulmonary Arterial Hypertension. Frontiers in medicine, 7, 81. (Read full article)

Commentary

  1. Jacobs JA, Ryan J (2021). Clinical uncertainty for the use of rivaroxaban in obesity. Journal of thrombosis and haemostasis, 19(3), 870-871. (Read full article)

Case Report

  1. Burkey BW, Jacobs JA, Aziz (2017). Temperature Instability in an Infant Treated with Propranolol for Infantile Hemangioma. The journal of pediatric pharmacology and therapeutics, 22(2), 124-127. (Read full article)

Editorial

  1. Hill MC, Jacobs JA, Wilcox J (2025). Revisiting Myocardial Recovery in Anthracycline Cardiomyopathy: Defining the Steps to Success in Contemporary Practice. Journal of cardiac failure, 31(9), 1390-1392. (Read full article)